Massive Bio has launched a new “Hub” designed to foster strategic partnerships with just-in-time (JIT) vendors and the clinical research teams of healthcare providers, in order to help facilitate what it hopes will be the world’s largest JIT oncology clinical trial network.
That network, Massive Bio said, is intended to combine the company’s advanced technology, oncology expertise, and patient engagement, along with newly developed capabilities from leading JIT services to form the world’s largest artificial intelligence (AI)-enabled oncology site network.
The network would strive to deliver accelerated patient enrollment services using a contracting model that offers cost and time certainty in trial delivery, with the goal of reducing operational barriers in clinical trial enrollment at point-of-care, Massive Bio said.
Selin Kurnaz, Ph.D., Co-founder and CEO of Massive Bio, said the company has emerged following several months in stealth mode, during which it sought to understand the pros-and-cons of leveraging JIT networks—an analysis that resulted in creating the Hub and its role of managing JIT oncology clinical trial networks.
“This first-in-class Hub is responsible for evaluating market players in the JIT arena, understanding the needs of pharmaceutical companies, and Contract Research Organizations, assessing the provider networks interested in opening JIT sites, and further enabling clinical research services to perform the highest patient enrollment potential,” Kurnaz said in a statement.
Kurnaz said Massive Bio is primarily looking for strategic partnerships and assessing key targets for acquisition. A half dozen JIT vendors and provider networks have expressed interest in partnering with the Hub, she said, adding that Massive Bio will announce “major” partnerships in the next couple of months.
“Beyond being a healthcare informatics company, we are the catalyzers and connectors of an entire oncology clinical research service industry, to accelerate drug development and increase efficiency, which is currently a very broken system,” Kurnaz asserted.
The company said its capabilities include its SYNERGY-AI platform, and a community of US-based oncology research sites, all pre-contracted, pre-qualified, and ready for rapid activation into a trial. Massive Bio’s expertise in precision oncology, AI-powered patient identification and patient engagement, combined with JIT solutions are.”
Massive Bio says its enrollment rate is four times higher than any leading precision oncology platform due to its dedicated focus on oncology, superior technology, sub-specialist supervision combined by clinical navigation support and outcomes collection.
“Massive Bio services pre-identified patients in your practice so that you no longer need to comb your database, ask for referrals, screen charts and keep track of all the inclusion and exclusion criteria of every study,” the company’s co-founder and Chief Medical Advisor Arturo Loaiza-Bonilla, M.D., MSEd, stated. “Our partners’ JIT capabilities jumpstart oncology trial enrollment and deliver the first patient faster, then continue to find patients to accelerate overall timelines.”
“We will continue partnering with innovative enterprises that are entrusted with the world’s most important research companies,” Loaiza-Bonilla added. “Together we look forward to delivering significant value to the oncology clinical trial space.”